HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1
Castration-resistant prostate cancer (CRPC) is refractory to hormone treatment, and its progression mechanism is not fully uncovered. This study aims to clarify the role and mechanism of Human antigen R (HuR) as a therapeutic target for CRPC progression. Overall design: HuR was knocked out by Cas9  in CRPC cell lines  PC3 and DU145. Subsequently, we collected RNA from the experimental and control groups.Compare gene expression profile analysis in the RNA-seq data.